Search results
Author(s):
Josep Rodés-Cabau
Added:
2 months ago
TCT 2025 - Short-term anticoagulation reduced adverse events following left atrial appendage closure (LAAC) compared to dual antiplatelet therapy (DAPT).Dr Josep Rodés-Cabau (Quebec Heart and Lung Institute, Quebec, CA) joins us at TCT 2025 to discuss findings from ANDES trial (NCT03568890) investigating the safety and efficacy of short-term anticoagulation versus DAPT for preventing device…
View more
Author(s):
Davide Capodanno
,
Sneha Shah Jain
Added:
4 months ago
Presented at the European Society of Cardiology (ESC) Congress 2025, Prof Carolyn Lam (Singapore, UK), Prof Davide Capodanno (Catania, IT), Dr Sneha Shah Jain (Stanford, US) and Prof Jeffrey Weitz (Hamilton, CA) examine the prevalence and challenges of stroke prevention in atrial fibrillation (AF) and after acute coronary syndrome (ACS). The faculty review current treatment guidelines, explore…
View more
Author(s):
Carolyn Lam
,
Jeffrey Weitz
Added:
4 months ago
Hear from Prof Carolyn Lam and Prof Jeffrey Weitz as they share key take-home messages from ESC 2025.Filmed onsite, this peer-to-peer discussion distils the latest updates in thrombosis management for acute coronary syndrome (ACS), secondary stroke prevention (SSP) and atrial fibrillation (AF).Register for the upcoming Q&A webinar, taking place on 6 October (14:00 EDT / 20:00 CEST), to put your…
View more
Author(s):
Carolyn Lam
,
Jeffrey Weitz
,
Sneha Shah Jain
Start date:
Oct 06, 2025
Following the ESC 2025 symposium 'Revolutionising Thrombosis Treatment in ACS, SSP and AF – Bridging the Gaps With Next Generation Anticoagulation Strategies', this live Q&A webinar offers an exclusive chance to continue the conversation.Join Prof Carolyn Lam (Singapore, UK), Prof Jeffrey Weitz (Hamilton, CA) and Dr Sneha Shah Jain (Stanford, US) as they address your questions on stroke…
View more
Author(s):
Harriette Van Spall
,
Isabelle Mahé
Added:
9 months ago
ACC 25 - The API-CAT Study shows reduced-dose apixaban is non-inferior to full-dose apixaban for extended anticoagulation in patients with active cancer who have completed 6 months of anticoagulant therapy for venous thromboembolism (VTE).Late-Breaker host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) is joined by Prof Isabelle Mahe (Paris Cite University, Paris, FR) to discuss the…
View more
Stavros Konstantinides
Job title: Professor for Clinical Trials and Medical Director of the Center for Thrombosis and Hemostasis
Author
Rita Paniccia
Job title: University Researcher
Author
Darko Antic
Job title: Professor of Internal Medicine
Author
Arina ten Cate-Hoek
Job title: Associate Professor of Medicine, FHML; Medical Director, Anticoagulation Clinic, Maastricht University Medical Center
Author
Jeffrey Weitz
Research Area(s) / Expertise:
Job title: Professor of Medicine and Biochemistry and Biomedical Sciences & Executive Director
Author